Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIBVax
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
FIBVax is an investigational therapeutic vaccine developed by West China Hospital of Sichuan University for the treatment of diffuse cutaneous systemic sclerosis (dcSSc) and associated interstitial lung disease (SSc-ILD). The vaccine is designed to elicit a targeted immune response against activated fibroblasts, which are the primary drivers of pathological collagen deposition and tissue fibrosis in systemic sclerosis. Specifically, FIBVax targets **Fibroblast Activation Protein alpha (FAP)**, a marker highly expressed on activated fibroblasts but minimally present in normal adult tissues. By inducing an immune-mediated depletion or inhibition of these fibrotic cells, FIBVax aims to reduce skin thickening and improve lung function. It is currently being evaluated in a Phase 1, single-arm, open-label clinical trial to assess its safety, tolerability, optimal dosing, and preliminary immunogenicity in adult patients.
- Brand names
- FIBVax
- Other names
- FIBVax
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on FIBVax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIBVax.